SCHEMBL3026850

SCHEMBL3026850

CCCCCCC(CCCC)N[C]=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 2/20 0.41
MAPT P10636 1/20 0.41
PLA2G2C Q5R387 2/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39
CA2 P00918 1/20 0.39
FDPS P14324 4/20 0.38
GPR84 Q9NQS5 3/20 0.38
FFAR1 O14842 1/20 0.38
PLA2G2A P14555 1/20 0.37
ZDHHC7 Q9NXF8 1/20 0.37
LMNA P02545 1/20 0.37
LCK P06239 1/20 0.36
PPARD Q03181 1/20 0.36
ZDHHC20 Q5W0Z9 1/20 0.36
ZDHHC2 Q9UIJ5 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11110929 1.00 DNM1 (0.41) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL11111748 0.98 MAPT (0.42) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL270098 0.98 MAPT (0.38) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL270648 0.96 MAPT (0.39) MAPTPLA2G2CADH1BADH1CADH1A
SCHEMBL277536 0.94 MAPT (0.39) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL271666 0.93 PLA2G2C (0.35) DNM1MAPTPLA2G2CCA2FDPS
SCHEMBL271828 0.91 MAPT (0.36) MAPTPLA2G2CADH1BADH1CADH1A
SCHEMBL22395233 0.89 MAPT (0.39) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL4978853 0.89 MAPT (0.39) DNM1MAPTPLA2G2CADH1BADH1C
SCHEMBL271367 0.89 PLA2G2C (0.33) DNM1PLA2G2CCA2FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745002-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-11-03 EP disclosed
US-20100210653-A1 Novel Compounds, Their Preparations and Use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-19 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080114036-A1 Novel Compounds, Their Preparations And Use NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1745002-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP disclosed
WO-2005105725-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B DNM1 1127/4885MAPT 1563/4885PLA2G2C 2503/4885
US-20100210653-A1 Novel Compounds, Their Preparations and Use PPARG, PPARD, PPARA DNM1 2246/4885MAPT 3336/4885PLA2G2C 457/4885
US-20080114036-A1 Novel Compounds, Their Preparations And Use PPARG, PPARD, GPR119 DNM1 1964/4885MAPT 3929/4885PLA2G2C 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.